{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:49:51Z","timestamp":1792039791142,"version":"4.4.0"},"reference-count":165,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00044-026-03595-6","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:16:39Z","timestamp":1786079799000},"page":"1951-1974","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in nucleotide-based P2Y\u2081 antagonism: implications for cardiovascular therapeutics"],"prefix":"10.1007","volume":"35","author":[{"given":"Nandanan","family":"Erathodiyil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineesh V.","family":"Raveendran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie Y.","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"1","key":"3595_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5334\/gh.1288","volume":"19","author":"M Di Cesare","year":"2024","unstructured":"Di Cesare M, Perel P, Taylor S, Kabudula C, Bixby H, Gaziano TA, et al. The Heart of the World. Glob Heart. 2024;19(1):11. https:\/\/doi.org\/10.5334\/gh.1288.","journal-title":"Glob Heart"},{"key":"3595_CR2","doi-asserted-by":"publisher","unstructured":"Sanad Shujaaa A, Sulaiman Mohammed Abdullah A, Khaled Mohamed Nahil A, Amer Obelk Attya A, Alsahli, Hassan G, et al. Global Burden, Risk Factors, and Evidence-Based Strategies for Cardiovascular Disease Prevention: A Comprehensive Systematic Review. J Angiotherapy. 2025;9(1) :9110348. https:\/\/doi.org\/10.25163\/angiotherapy.9110348","DOI":"10.25163\/angiotherapy.9110348"},{"key":"3595_CR3","doi-asserted-by":"publisher","unstructured":"Yang H, Ma Q, Han L, Liu H. A global prediction of cardiovascular disease from 2020 to 2030. Front Cardiovasc Med. 2025;12: 1462705. . https:\/\/doi.org\/10.3389\/fcvm.2025.1462705","DOI":"10.3389\/fcvm.2025.1462705"},{"key":"3595_CR4","unstructured":"Deaths from cardiovascular. disease surged 60% glosbal y over the last 30 years. World Heart Federation Report; 2025."},{"key":"3595_CR5","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/978-0-387-09834-0_35","volume-title":"Handbook of Epidemiology","author":"DR Labarthe","year":"2014","unstructured":"Labarthe DR. Cardiovascular Health and Disease. In: Ahrens W, Pigeot I, editors. Handbook of Epidemiology. New York, NY: Springer New York; 2014. pp. 2121\u201357."},{"issue":"1","key":"3595_CR6","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41392-025-02346-0","volume":"10","author":"MJ Herzog","year":"2025","unstructured":"Herzog MJ, M\u00fcller P, Lechner K, Stiebler M, Arndt P, Kunz M, et al. Arterial stiffness and vascular aging: mechanisms, prevention, and therapy. Signal Transduct Target Therapy. 2025;10(1):282. https:\/\/doi.org\/10.1038\/s41392-025-02346-0.","journal-title":"Signal Transduct Target Therapy"},{"key":"3595_CR7","doi-asserted-by":"publisher","first-page":"1264319","DOI":"10.3389\/fcvm.2023.1264319","volume":"10","author":"E Reijnders","year":"2023","unstructured":"Reijnders E, van der Laarse A, Jukema JW, Cobbaert CM. High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine. Front Cardiovasc Med. 2023;10:1264319. https:\/\/doi.org\/10.3389\/fcvm.2023.1264319.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"3595_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41392-021-00553-z","volume":"6","author":"Z Huang","year":"2021","unstructured":"Huang Z, Xie N, Illes P, Di Virgilio F, Ulrich H, Semyanov A, et al. From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct Target Ther. 2021;6(1):162. https:\/\/doi.org\/10.1038\/s41392-021-00553-z.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3595_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11302-020-09734-x","volume":"17","author":"V Ralevic","year":"2021","unstructured":"Ralevic V. Purinergic signalling in the cardiovascular system-a tribute to Geoffrey Burnstock. Purinergic Signal. 2021;17(1):63\u20139. https:\/\/doi.org\/10.1007\/s11302-020-09734-x.","journal-title":"Purinergic Signal"},{"issue":"1","key":"3595_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1161\/CIRCRESAHA.116.309726","volume":"120","author":"G Burnstock","year":"2017","unstructured":"Burnstock G. Purinergic Signaling in the Cardiovascular System. Circul Res. 2017;120(1):207\u201328. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.309726.","journal-title":"Circul Res"},{"issue":"1","key":"3595_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11302-007-9078-7","volume":"4","author":"D Erlinge","year":"2008","unstructured":"Erlinge D, Burnstock G. P2 receptors in cardiovascular regulation and disease. Purinergic Signal. 2008;4(1):1\u201320. https:\/\/doi.org\/10.1007\/s11302-007-9078-7.","journal-title":"Purinergic Signal"},{"issue":"1","key":"3595_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s11302-022-09856-4","volume":"19","author":"Y Zhuang","year":"2023","unstructured":"Zhuang Y, Yu ML, Lu SF. Purinergic signaling in myocardial ischemia-reperfusion injury. Purinergic Signal. 2023;19(1):229\u201343. https:\/\/doi.org\/10.1007\/s11302-022-09856-4.","journal-title":"Purinergic Signal"},{"issue":"1","key":"3595_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/rth2.12266","volume":"4","author":"J Rayes","year":"2020","unstructured":"Rayes J, Bourne JH, Brill A, Watson SP. The dual role of platelet-innate immune cell interactions in thrombo-inflammation. Res Pract Thromb Haemost. 2020;4(1):23\u201335. https:\/\/doi.org\/10.1002\/rth2.12266.","journal-title":"Res Pract Thromb Haemost"},{"key":"3595_CR14","doi-asserted-by":"publisher","unstructured":"Qian Y, Zheng Y, Leng L, Liu Q, Tian X, Chen S, et al. Adenosine and adenosine receptors: a double-edged sword in cardiovascular system. Front Pharmacol. 2025;16:1538680. https:\/\/doi.org\/10.3389\/fphar.2025.1538680","DOI":"10.3389\/fphar.2025.1538680"},{"issue":"1","key":"3595_CR15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11302-021-09839-x","volume":"19","author":"X-M Wu","year":"2023","unstructured":"Wu X-M, Zhang N, Li J-S, Yang Z-H, Huang X-L, Yang X-F. Purinergic receptors mediate endothelial dysfunction and participate in atherosclerosis. Purinergic Signalling. 2023;19(1):265\u201372. https:\/\/doi.org\/10.1007\/s11302-021-09839-x.","journal-title":"Purinergic Signalling"},{"issue":"1","key":"3595_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1124\/pr.113.008029","volume":"66","author":"G Burnstock","year":"2014","unstructured":"Burnstock G, Ralevic V. Purinergic signaling and blood vessels in health and disease. Pharmacol Rev. 2014;66(1):102\u201392. https:\/\/doi.org\/10.1124\/pr.113.008029.","journal-title":"Pharmacol Rev"},{"issue":"2","key":"3595_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1055\/s-2005-869519","volume":"31","author":"JM Boeynaems","year":"2005","unstructured":"Boeynaems JM, Communi D, Gonzalez NS, Robaye B. Overview of the P2 receptors. Semin Thromb Hemost. 2005;31(2):139\u201349. https:\/\/doi.org\/10.1055\/s-2005-869519.","journal-title":"Semin Thromb Hemost"},{"issue":"1","key":"3595_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/wmts.1","volume":"1","author":"N-i-H Syed","year":"2012","unstructured":"Syed N-i-H, Kennedy C. Pharmacology of P2X receptors. Wiley Interdisciplinary Reviews: Membrane Transp Signal. 2012;1(1):16\u201330. https:\/\/doi.org\/10.1002\/wmts.1.","journal-title":"Wiley Interdisciplinary Reviews: Membrane Transp Signal"},{"key":"3595_CR19","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.neuropharm.2015.10.030","volume":"104","author":"I von K\u00fcgelgen","year":"2016","unstructured":"von K\u00fcgelgen I, Hoffmann K. Pharmacology and structure of P2Y receptors. Neuropharmacology. 2016;104:50\u201361. https:\/\/doi.org\/10.1016\/j.neuropharm.2015.10.030.","journal-title":"Neuropharmacology"},{"issue":"1","key":"3595_CR20","doi-asserted-by":"publisher","first-page":"8490","DOI":"10.1038\/s41467-024-52636-4","volume":"15","author":"AC Oken","year":"2024","unstructured":"Oken AC, Lisi NE, Ditter IA, Shi H, Nechiporuk NA, Mansoor SE. Cryo-EM structures of the human P2X1 receptor reveal subtype-specific architecture and antagonism by supramolecular ligand-binding. Nat Commun. 2024;15(1):8490. https:\/\/doi.org\/10.1038\/s41467-024-52636-4.","journal-title":"Nat Commun"},{"issue":"6","key":"3595_CR21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/00005344-200212000-00005","volume":"40","author":"L Wang","year":"2002","unstructured":"Wang L, Karlsson L, Moses S, Hultg\u00e5rdh-Nilsson A, Andersson M, Borna C, et al. P2 receptor expression profiles in human vascular smooth muscle and endothelial cells. J Cardiovasc Pharmacol. 2002;40(6):841\u201353. https:\/\/doi.org\/10.1097\/00005344-200212000-00005.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"3595_CR22","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1007\/s12185-012-1188-5","volume":"96","author":"F Moheimani","year":"2012","unstructured":"Moheimani F, Jackson DE. P2Y12 receptor: platelet thrombus formation and medical interventions. Int J Hematol. 2012;96(5):572\u201387. https:\/\/doi.org\/10.1007\/s12185-012-1188-5.","journal-title":"Int J Hematol"},{"issue":"2","key":"3595_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11302-023-09963-w","volume":"20","author":"I von K\u00fcgelgen","year":"2024","unstructured":"von K\u00fcgelgen I. Pharmacological characterization of P2Y receptor subtypes - an update. Purinergic Signal. 2024;20(2):99\u2013108. https:\/\/doi.org\/10.1007\/s11302-023-09963-w.","journal-title":"Purinergic Signal"},{"issue":"6","key":"3595_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/09537109975870","volume":"10","author":"YB Kim","year":"1999","unstructured":"Kim YB, Jin J, Dangelmaier C, Daniel JL, Kunapuli SP. The P2Y1 receptor is essential for ADP-induced shape change and aggregation in mouse platelets. Platelets. 1999;10(6):399\u2013406. https:\/\/doi.org\/10.1080\/09537109975870.","journal-title":"Platelets"},{"issue":"6","key":"3595_CR25","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/j.1538-7836.2004.00722.x","volume":"2","author":"P Mangin","year":"2004","unstructured":"Mangin P, Ohlmann P, Eckly A, Cazenave JP, Lanza F, Gachet C. The P2Y1receptor plays an essential role in the platelet shape change induced by collagen when TxA2 formation is prevented. J Thromb Haemost. 2004;2(6):969\u201377. . https:\/\/doi.org\/10.1111\/j.1538-7836.2004.00722.x","journal-title":"J Thromb Haemost"},{"issue":"2","key":"3595_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s11302-013-9393-0","volume":"10","author":"IA Jagroop","year":"2014","unstructured":"Jagroop IA. Plant extracts inhibit ADP-induced platelet activation in humans: their potential therapeutic role as ADP antagonists. Purinergic Signal. 2014;10(2):233\u20139. https:\/\/doi.org\/10.1007\/s11302-013-9393-0.","journal-title":"Purinergic Signal"},{"issue":"7","key":"3595_CR27","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/j.jtha.2023.03.013","volume":"21","author":"DS Paul","year":"2023","unstructured":"Paul DS, Blatt TN, Schug WJ, Clark EG, Kawano T, Mackman N, et al. Loss of P2Y(1) receptor desensitization does not impact hemostasis or thrombosis despite increased platelet reactivity in vitro. J Thromb Haemost. 2023;21(7):1891\u2013902. https:\/\/doi.org\/10.1016\/j.jtha.2023.03.013.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"3595_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0014-5793(93)81397-i","volume":"324","author":"TE Webb","year":"1993","unstructured":"Webb TE, Simon J, Krishek BJ, Bateson AN, Smart TG, King BF, et al. Cloning and functional expression of a brain G-protein-coupled ATP receptor. FEBS Lett. 1993;324(2):219\u201325. https:\/\/doi.org\/10.1016\/0014-5793(93)81397-i.","journal-title":"FEBS Lett"},{"issue":"2","key":"3595_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/0378-1119(96)00027-3","volume":"171","author":"C L\u00e9on","year":"1996","unstructured":"L\u00e9on C, Vial C, Cazenave JP, Gachet C. Cloning and sequencing of a human cDNA encoding endothelial P2Y1 purinoceptor. Gene. 1996;171(2):295\u20137. https:\/\/doi.org\/10.1016\/0378-1119(96)00027-3.","journal-title":"Gene"},{"issue":"2","key":"3595_CR30","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1055\/s-2005-869520","volume":"31","author":"B Hechler","year":"2005","unstructured":"Hechler B, Cattaneo M, Gachet C. The P2 receptors in platelet function. Semin Thromb Hemost. 2005;31(2):150\u201361. https:\/\/doi.org\/10.1055\/s-2005-869520.","journal-title":"Semin Thromb Hemost"},{"issue":"2","key":"3595_CR31","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.pharmthera.2005.03.009","volume":"108","author":"C Gachet","year":"2005","unstructured":"Gachet C. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther. 2005;108(2):180\u201392. https:\/\/doi.org\/10.1016\/j.pharmthera.2005.03.009.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"3595_CR32","doi-asserted-by":"publisher","first-page":"431","DOI":"10.4155\/fmc.13.6","volume":"5","author":"C Kennedy","year":"2013","unstructured":"Kennedy C, Chootip K, Mitchell C, Syed NI, Tengah A. P2X and P2Y nucleotide receptors as targets in cardiovascular disease. Future Med Chem. 2013;5(4):431\u201349. https:\/\/doi.org\/10.4155\/fmc.13.6.","journal-title":"Future Med Chem"},{"issue":"1\u20133","key":"3595_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000095180","volume":"18","author":"M Montiel","year":"2006","unstructured":"Montiel M, de la Blanca EP, Jim\u00e9nez E. P2Y receptors activate MAPK\/ERK through a pathway involving PI3K\/PDK1\/PKC-zeta in human vein endothelial cells. Cell Physiol Biochem. 2006;18(1\u20133):123\u201334. https:\/\/doi.org\/10.1159\/000095180.","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"3595_CR34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11302-022-09885-z","volume":"19","author":"M-J Wang","year":"2023","unstructured":"Wang M-J, Yang B-R, Jing X-Y, Wang Y-Z, Kang L, Ren K, et al. P2Y1R and P2Y2R: potential molecular triggers in muscle regeneration. Purinergic Signalling. 2023;19(1):305\u201313. https:\/\/doi.org\/10.1007\/s11302-022-09885-z.","journal-title":"Purinergic Signalling"},{"issue":"3","key":"3595_CR35","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1160\/th07-11-0673","volume":"99","author":"C Gachet","year":"2008","unstructured":"Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost. 2008;99(3):466\u201372. https:\/\/doi.org\/10.1160\/th07-11-0673.","journal-title":"Thromb Haemost"},{"key":"3595_CR36","doi-asserted-by":"publisher","first-page":"109311","DOI":"10.1016\/j.neuropharm.2022.109311","volume":"223","author":"C Lohr","year":"2023","unstructured":"Lohr C. Role of P2Y receptors in astrocyte physiology and pathophysiology. Neuropharmacology. 2023;223:109311. https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109311.","journal-title":"Neuropharmacology"},{"issue":"8","key":"3595_CR37","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1113\/jphysiol.2011.224634","volume":"590","author":"SJ Hwang","year":"2012","unstructured":"Hwang SJ, Blair PJ, Durnin L, Mutafova-Yambolieva V, Sanders KM, Ward SM. P2Y1 purinoreceptors are fundamental to inhibitory motor control of murine colonic excitability and transit. J Physiol. 2012;590(8):1957\u201372. https:\/\/doi.org\/10.1113\/jphysiol.2011.224634.","journal-title":"J Physiol"},{"issue":"4","key":"3595_CR38","doi-asserted-by":"publisher","first-page":"e1464","DOI":"10.1002\/wcms.1464","volume":"10","author":"A Neumann","year":"2020","unstructured":"Neumann A, M\u00fcller CE, Namasivayam V. P2Y1-like nucleotide receptors\u2014Structures, molecular modeling, mutagenesis, and oligomerization. WIREs Comput Mol Sci. 2020;10(4):e1464. https:\/\/doi.org\/10.1002\/wcms.1464.","journal-title":"WIREs Comput Mol Sci"},{"issue":"9","key":"3595_CR39","doi-asserted-by":"publisher","first-page":"9057","DOI":"10.1021\/acs.jmedchem.5c00249","volume":"68","author":"M Puthanveedu","year":"2025","unstructured":"Puthanveedu M, Knight R, Stocks MJ. Drug-like Antagonists of P2Y Receptor Subtypes: An Update. J Med Chem. 2025;68(9):9057\u201383. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00249.","journal-title":"J Med Chem"},{"issue":"11","key":"3595_CR40","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1016\/j.bmcl.2008.04.028","volume":"18","author":"JA Pfefferkorn","year":"2008","unstructured":"Pfefferkorn JA, Choi C, Winters T, Kennedy R, Chi L, Perrin LA, et al. P2Y1 receptor antagonists as novel antithrombotic agents. Bioorg Med Chem Lett. 2008;18(11):3338\u201343. https:\/\/doi.org\/10.1016\/j.bmcl.2008.04.028.","journal-title":"Bioorg Med Chem Lett"},{"key":"3595_CR41","doi-asserted-by":"publisher","first-page":"118479","DOI":"10.1016\/j.bmc.2025.118479","volume":"132","author":"X Liu","year":"2026","unstructured":"Liu X, Ma S, Yao Y, Duan Y, Li R, Song C. The role of P2Y(1)R in cardiovascular diseases and recent development of P2Y(1)R antagonists. Bioorg Med Chem. 2026;132:118479. https:\/\/doi.org\/10.1016\/j.bmc.2025.118479.","journal-title":"Bioorg Med Chem"},{"issue":"9","key":"3595_CR42","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1021\/jm980657j","volume":"42","author":"E Nandanan","year":"1999","unstructured":"Nandanan E, Camaioni E, Jang SY, Kim YC, Cristalli G, Herdewijn P, et al. Structure-activity relationships of bisphosphate nucleotide derivatives as P2Y1 receptor antagonists and partial agonists. J Med Chem. 1999;42(9):1625\u201338. https:\/\/doi.org\/10.1021\/jm980657j.","journal-title":"J Med Chem"},{"issue":"5","key":"3595_CR43","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1021\/jm990249v","volume":"43","author":"E Nandanan","year":"2000","unstructured":"Nandanan E, Jang SY, Moro S, Kim HO, Siddiqui MA, Russ P, et al. Synthesis, biological activity, and molecular modeling of ribose-modified deoxyadenosine bisphosphate analogues as P2Y(1) receptor ligands. J Med Chem. 2000;43(5):829\u201342. https:\/\/doi.org\/10.1021\/jm990249v.","journal-title":"J Med Chem"},{"issue":"6","key":"3595_CR44","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2174\/138620708784911474","volume":"11","author":"D Houston","year":"2008","unstructured":"Houston D, Costanzi S, Jacobson KA, Harden TK. Development of selective high affinity antagonists, agonists, and radioligands for the P2Y1 receptor. Comb Chem High Throughput Screen. 2008;11(6):410\u20139. https:\/\/doi.org\/10.2174\/138620708784911474.","journal-title":"Comb Chem High Throughput Screen"},{"issue":"5","key":"3595_CR45","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/sj.bjp.0706453","volume":"147","author":"D Houston","year":"2006","unstructured":"Houston D, Ohno M, Nicholas RA, Jacobson KA, Harden TK. [32P]2-iodo-N6-methyl-(N)-methanocarba-2\u2019-deoxyadenosine-3\u2019,5\u2019-bisphosphate ([32P]MRS2500), a novel radioligand for quantification of native P2Y1 receptors. Br J Pharmacol. 2006;147(5):459\u201367. https:\/\/doi.org\/10.1038\/sj.bjp.0706453.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"3595_CR46","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1124\/mol.65.2.426","volume":"65","author":"GL Waldo","year":"2004","unstructured":"Waldo GL, Harden TK. Agonist binding and Gq-stimulating activities of the purified human P2Y1 receptor. Mol Pharmacol. 2004;65(2):426\u201336. https:\/\/doi.org\/10.1124\/mol.65.2.426.","journal-title":"Mol Pharmacol"},{"issue":"2","key":"3595_CR47","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1124\/jpet.105.094037","volume":"316","author":"B Hechler","year":"2006","unstructured":"Hechler B, Nonne C, Roh EJ, Cattaneo M, Cazenave JP, Lanza F, et al. MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2\u2019-deoxyadenosine-3\u2019,5\u2019-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. J Pharmacol Exp Ther. 2006;316(2):556\u201363. https:\/\/doi.org\/10.1124\/jpet.105.094037.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"3595_CR48","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1476-5381.1994.tb17034.x","volume":"113","author":"JL Boyer","year":"1994","unstructured":"Boyer JL, Zohn IE, Jacobson KA, Harden TK. Differential effects of P2-purinoceptor antagonists on phospholipase C- and adenylyl cyclase-coupled P2Y-purinoceptors. Br J Pharmacol. 1994;113(2):614\u201320. https:\/\/doi.org\/10.1111\/j.1476-5381.1994.tb17034.x.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"3595_CR49","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/j.1476-5381.1996.tb16038.x","volume":"119","author":"SJ Charlton","year":"1996","unstructured":"Charlton SJ, Brown CA, Weisman GA, Turner JT, Erb L, Boarder MR. Cloned and transfected P2Y4 receptors: characterization of a suramin and PPADS-insensitive response to UTP. Br J Pharmacol. 1996;119(7):1301\u20133. https:\/\/doi.org\/10.1111\/j.1476-5381.1996.tb16038.x.","journal-title":"Br J Pharmacol"},{"issue":"26","key":"3595_CR50","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.2174\/1381612023392973","volume":"8","author":"G Lambrecht","year":"2002","unstructured":"Lambrecht G, Braun K, Damer S, Ganso M, Hildebrandt C, Ullmann H, et al. Structure-Activity Relationships of Suramin and Pyridoxal-5\u2019-phosphate Derivatives as P2 Receptor Antagonists. Curr Pharm Design. 2002;8(26):2371\u201399. https:\/\/doi.org\/10.2174\/1381612023392973.","journal-title":"Curr Pharm Design"},{"issue":"5","key":"3595_CR51","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/S0026-895X(25)09561-6","volume":"50","author":"JL Boyer","year":"1996","unstructured":"Boyer JL, Romero-Avila T, Schachter JB, Harden TK. Identification of competitive antagonists of the P2Y1 receptor. Mol Pharmacol. 1996;50(5):1323\u20139.","journal-title":"Mol Pharmacol"},{"issue":"3","key":"3595_CR52","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1124\/pr.58.3.3","volume":"58","author":"MP Abbracchio","year":"2006","unstructured":"Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, et al. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev. 2006;58(3):281\u2013341. https:\/\/doi.org\/10.1124\/pr.58.3.3.","journal-title":"Pharmacol Rev"},{"issue":"4","key":"3595_CR53","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1074\/jbc.273.4.2030","volume":"273","author":"J Jin","year":"1998","unstructured":"Jin J, Daniel JL, Kunapuli SP. Molecular Basis for ADP-induced Platelet Activation: II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem. 1998;273(4):2030\u20134. https:\/\/doi.org\/10.1074\/jbc.273.4.2030.","journal-title":"J Biol Chem"},{"issue":"1","key":"3595_CR54","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1182\/blood.V92.1.152.413k27_152_159","volume":"92","author":"B Hechler","year":"1998","unstructured":"Hechler B, L\u00e9on C, Vial C, Vigne P, Frelin C, Cazenave JP, et al. The P2Y1 receptor is necessary for adenosine 5\u2019-diphosphate-induced platelet aggregation. Blood. 1998;92(1):152\u20139.","journal-title":"Blood"},{"issue":"2","key":"3595_CR55","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1021\/jm970433l","volume":"41","author":"E Camaioni","year":"1998","unstructured":"Camaioni E, Boyer JL, Mohanram A, Harden TK, Jacobson KA. Deoxyadenosine bisphosphate derivatives as potent antagonists at P2Y1 receptors. J Med Chem. 1998;41(2):183\u201390. https:\/\/doi.org\/10.1021\/jm970433l.","journal-title":"J Med Chem"},{"issue":"24","key":"3595_CR56","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1021\/jm00076a023","volume":"36","author":"B Fischer","year":"1993","unstructured":"Fischer B, Boyer JL, Hoyle CH, Ziganshin AU, Brizzolara AL, Knight GE, et al. Identification of potent, selective P2Y-purinoceptor agonists: structure-activity relationships for 2-thioether derivatives of adenosine 5\u2019-triphosphate. J Med Chem. 1993;36(24):3937\u201346. https:\/\/doi.org\/10.1021\/jm00076a023.","journal-title":"J Med Chem"},{"issue":"6","key":"3595_CR57","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1111\/j.1476-5381.2009.00454.x","volume":"158","author":"L Grasa","year":"2009","unstructured":"Grasa L, Gil V, Gallego D, Mart\u00edn MT, Jim\u00e9nez M. P2Y(1) receptors mediate inhibitory neuromuscular transmission in the rat colon. Br J Pharmacol. 2009;158(6):1641\u201352. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00454.x.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"3595_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/sj.bjp.0701837","volume":"124","author":"JL Boyer","year":"1998","unstructured":"Boyer JL, Mohanram A, Camaioni E, Jacobson KA, Harden TK. Competitive and selective antagonism of P2Y1 receptors by N6-methyl 2\u2019-deoxyadenosine 3\u2019,5\u2019-bisphosphate. Br J Pharmacol. 1998;124(1):1\u20133. https:\/\/doi.org\/10.1038\/sj.bjp.0701837.","journal-title":"Br J Pharmacol"},{"issue":"27","key":"3595_CR59","doi-asserted-by":"publisher","first-page":"6286","DOI":"10.1523\/jneurosci.0628-05.2005","volume":"25","author":"RJ Rodrigues","year":"2005","unstructured":"Rodrigues RJ, Almeida T, Richardson PJ, Oliveira CR, Cunha RA. Dual presynaptic control by ATP of glutamate release via facilitatory P2X1, P2X2\/3, and P2X3 and inhibitory P2Y1, P2Y2, and\/or P2Y4 receptors in the rat hippocampus. J Neurosci. 2005;25(27):6286\u201395. https:\/\/doi.org\/10.1523\/jneurosci.0628-05.2005.","journal-title":"J Neurosci"},{"issue":"8","key":"3595_CR60","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.bcp.2006.07.017","volume":"72","author":"LK Mamedova","year":"2006","unstructured":"Mamedova LK, Gao ZG, Jacobson KA. Regulation of death and survival in astrocytes by ADP activating P2Y1 and P2Y12 receptors. Biochem Pharmacol. 2006;72(8):1031\u201341. https:\/\/doi.org\/10.1016\/j.bcp.2006.07.017.","journal-title":"Biochem Pharmacol"},{"issue":"19","key":"3595_CR61","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1021\/jm010082h","volume":"44","author":"HS Kim","year":"2001","unstructured":"Kim HS, Barak D, Harden TK, Boyer JL, Jacobson KA. Acyclic and cyclopropyl analogues of adenosine bisphosphate antagonists of the P2Y1 receptor: structure-activity relationships and receptor docking. J Med Chem. 2001;44(19):3092\u2013108. https:\/\/doi.org\/10.1021\/jm010082h.","journal-title":"J Med Chem"},{"key":"3595_CR62","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.antiviral.2018.04.004","volume":"154","author":"KL Seley-Radtke","year":"2018","unstructured":"Seley-Radtke KL, Yates MK. The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. Antiviral Res. 2018;154:66\u201386. https:\/\/doi.org\/10.1016\/j.antiviral.2018.04.004.","journal-title":"Antiviral Res"},{"issue":"10","key":"3595_CR63","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1016\/j.bcp.2004.06.026","volume":"68","author":"M Cattaneo","year":"2004","unstructured":"Cattaneo M, Lecchi A, Ohno M, Joshi BV, Besada P, Tchilibon S, et al. Antiaggregatory activity in human platelets of potent antagonists of the P2Y 1 receptor. Biochem Pharmacol. 2004;68(10):1995\u20132002. https:\/\/doi.org\/10.1016\/j.bcp.2004.06.026.","journal-title":"Biochem Pharmacol"},{"issue":"26","key":"3595_CR64","doi-asserted-by":"publisher","first-page":"5694","DOI":"10.1021\/jm020173u","volume":"45","author":"B Xu","year":"2002","unstructured":"Xu B, Stephens A, Kirschenheuter G, Greslin AF, Cheng X, Sennelo J, et al. Acyclic analogues of adenosine bisphosphates as P2Y receptor antagonists: phosphate substitution leads to multiple pathways of inhibition of platelet aggregation. J Med Chem. 2002;45(26):5694\u2013709. https:\/\/doi.org\/10.1021\/jm020173u.","journal-title":"J Med Chem"},{"issue":"4","key":"3595_CR65","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1021\/jm9905211","volume":"43","author":"YC Kim","year":"2000","unstructured":"Kim YC, Gallo-Rodriguez C, Jang SY, Nandanan E, Adams M, Harden TK, et al. Acyclic analogues of deoxyadenosine 3\u2019,5\u2019-bisphosphates as P2Y(1) receptor antagonists. J Med Chem. 2000;43(4):746\u201355. https:\/\/doi.org\/10.1021\/jm9905211.","journal-title":"J Med Chem"},{"issue":"2","key":"3595_CR66","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1124\/mol.114.095711","volume":"88","author":"KA Jacobson","year":"2015","unstructured":"Jacobson KA, Paoletta S, Katritch V, Wu B, Gao ZG, Zhao Q, et al. Nucleotides Acting at P2Y Receptors: Connecting Structure and Function. Mol Pharmacol. 2015;88(2):220\u201330. https:\/\/doi.org\/10.1124\/mol.114.095711.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"3595_CR67","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1021\/jm010369e","volume":"45","author":"HS Kim","year":"2002","unstructured":"Kim HS, Ravi RG, Marquez VE, Maddileti S, Wihlborg AK, Erlinge D, et al. Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors. J Med Chem. 2002;45(1):208\u201318. https:\/\/doi.org\/10.1021\/jm010369e.","journal-title":"J Med Chem"},{"issue":"10","key":"3595_CR68","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1021\/jm010538v","volume":"45","author":"RG Ravi","year":"2002","unstructured":"Ravi RG, Kim HS, Servos J, Zimmermann H, Lee K, Maddileti S, et al. Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists. J Med Chem. 2002;45(10):2090\u2013100. https:\/\/doi.org\/10.1021\/jm010538v.","journal-title":"J Med Chem"},{"issue":"19","key":"3595_CR69","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1021\/jm960306+","volume":"39","author":"VE Marquez","year":"1996","unstructured":"Marquez VE, Siddiqui MA, Ezzitouni A, Russ P, Wang J, Wagner RW, et al. Nucleosides with a twist. Can fixed forms of sugar ring pucker influence biological activity in nucleosides and oligonucleotides? J Med Chem. 1996;39(19):3739\u201347. https:\/\/doi.org\/10.1021\/jm960306+.","journal-title":"J Med Chem"},{"issue":"6","key":"3595_CR70","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1124\/mi.4.6.7","volume":"4","author":"KA Jacobson","year":"2004","unstructured":"Jacobson KA, Kim SK, Costanzi S, Gao ZG. Purine receptors: GPCR structure and agonist design. Mol Interv. 2004;4(6):337\u201347. https:\/\/doi.org\/10.1124\/mi.4.6.7.","journal-title":"Mol Interv"},{"issue":"4","key":"3595_CR71","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1538-7836.2006.01866.x","volume":"4","author":"DM Bourdon","year":"2006","unstructured":"Bourdon DM, Mahanty SK, Jacobson KA, Boyer JL, Harden TK. (N)-methanocarba-2MeSADP (MRS2365) is a subtype-specific agonist that induces rapid desensitization of the P2Y1 receptor of human platelets. J Thromb Haemost. 2006;4(4):861\u20138. https:\/\/doi.org\/10.1111\/j.1538-7836.2006.01866.x.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"3595_CR72","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S0026-895X(25)12748-X","volume":"8","author":"G Gough","year":"1972","unstructured":"Gough G, Maguire MH, Penglis F. Analogues of adenosine 5\u2019-diphosphate-new platelet aggregators. Influence of purine ring and and phosphate chain substitutions on the platelet-aggregating potency of adenosine 5\u2019-diphosphate. Mol Pharmacol. 1972;8(2):170\u20137.","journal-title":"Mol Pharmacol"},{"issue":"23","key":"3595_CR73","doi-asserted-by":"publisher","first-page":"4974","DOI":"10.1021\/jm030127+","volume":"46","author":"HS Kim","year":"2003","unstructured":"Kim HS, Ohno M, Xu B, Kim HO, Choi Y, Ji XD, et al. 2-Substitution of adenine nucleotide analogues containing a bicyclo[3.1.0]hexane ring system locked in a northern conformation: enhanced potency as P2Y1 receptor antagonists. J Med Chem. 2003;46(23):4974\u201387. https:\/\/doi.org\/10.1021\/jm030127+.","journal-title":"J Med Chem"},{"issue":"5","key":"3595_CR74","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1124\/mol.62.5.1249","volume":"62","author":"GL Waldo","year":"2002","unstructured":"Waldo GL, Corbitt J, Boyer JL, Ravi G, Kim HS, Ji X-d, et al. Quantitation of the P2Y1 Receptor with a High Affinity Radiolabeled Antagonist. Mol Pharmacol. 2002;62(5):1249\u201357. https:\/\/doi.org\/10.1124\/mol.62.5.1249.","journal-title":"Mol Pharmacol"},{"issue":"4","key":"3595_CR75","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.phrs.2010.05.007","volume":"62","author":"P Ohlmann","year":"2010","unstructured":"Ohlmann P, de Castro S, Brown GG Jr., Gachet C, Jacobson KA, Harden TK. Quantification of recombinant and platelet P2Y(1) receptors utilizing a [(125)I]-labeled high-affinity antagonist 2-iodo-N(6)-methyl-(N)-methanocarba-2\u2019-deoxyadenosine-3\u2019,5\u2019-bisphosphate ([(125)I]MRS2500). Pharmacol Res. 2010;62(4):344\u201351. https:\/\/doi.org\/10.1016\/j.phrs.2010.05.007.","journal-title":"Pharmacol Res"},{"issue":"3","key":"3595_CR76","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1124\/jpet.104.068650","volume":"311","author":"M Chhatriwala","year":"2004","unstructured":"Chhatriwala M, Ravi RG, Patel RI, Boyer JL, Jacobson KA, Harden TK. Induction of novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. J Pharmacol Exp Ther. 2004;311(3):1038\u201343. https:\/\/doi.org\/10.1124\/jpet.104.068650.","journal-title":"J Pharmacol Exp Ther"},{"issue":"7547","key":"3595_CR77","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nature14287","volume":"520","author":"D Zhang","year":"2015","unstructured":"Zhang D, Gao ZG, Zhang K, Kiselev E, Crane S, Wang J, et al. Two disparate ligand-binding sites in the human P2Y1 receptor. Nature. 2015;520(7547):317\u201321. https:\/\/doi.org\/10.1038\/nature14287.","journal-title":"Nature"},{"issue":"1","key":"3595_CR78","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12915-023-01528-y","volume":"21","author":"A Ribes","year":"2023","unstructured":"Ribes A, Garcia C, Gratacap MP, Kostenis E, Martinez LO, Payrastre B, et al. Platelet P2Y(1) receptor exhibits constitutive G protein signaling and \u03b2-arrestin 2 recruitment. BMC Biol. 2023;21(1):14. https:\/\/doi.org\/10.1186\/s12915-023-01528-y.","journal-title":"BMC Biol"},{"issue":"4","key":"3595_CR79","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3390\/neurosci3040043","volume":"3","author":"RJ Rodrigues","year":"2022","unstructured":"Rodrigues RJ, Figueira AS, Marques JM. P2Y1 Receptor as a Catalyst of Brain Neurodegeneration. NeuroSci. 2022;3(4):604\u201315. https:\/\/doi.org\/10.3390\/neurosci3040043.","journal-title":"NeuroSci"},{"key":"3595_CR80","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.phrs.2018.12.009","volume":"141","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Matsumoto T, Jankowski V, Pernow J, Mustafa SJ, Duncker DJ, et al. Uridine adenosine tetraphosphate and purinergic signaling in cardiovascular system: An update. Pharmacol Res. 2019;141:32\u201345. https:\/\/doi.org\/10.1016\/j.phrs.2018.12.009.","journal-title":"Pharmacol Res"},{"issue":"7","key":"3595_CR81","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1182\/blood-2013-09-402560","volume":"124","author":"M Idzko","year":"2014","unstructured":"Idzko M, Ferrari D, Riegel AK, Eltzschig HK. Extracellular nucleotide and nucleoside signaling in vascular and blood disease. Blood. 2014;124(7):1029\u201337. https:\/\/doi.org\/10.1182\/blood-2013-09-402560.","journal-title":"Blood"},{"issue":"4","key":"3595_CR82","doi-asserted-by":"publisher","first-page":"H723","DOI":"10.1152\/ajpheart.00417.2020","volume":"319","author":"B Wernly","year":"2020","unstructured":"Wernly B, Zhou Z. More purinergic receptors deserve attention as therapeutic targets for the treatment of cardiovascular disease. Am J Physiol Heart Circ Physiol. 2020;319(4):H723\u20139. https:\/\/doi.org\/10.1152\/ajpheart.00417.2020.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"3595_CR83","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jare.2024.03.027","volume":"69","author":"Y Guo","year":"2025","unstructured":"Guo Y, Mao T, Fang Y, Wang H, Yu J, Zhu Y, et al. Comprehensive insights into potential roles of purinergic P2 receptors on diseases: Signaling pathways involved and potential therapeutics. J Adv Res. 2025;69:427\u201348. https:\/\/doi.org\/10.1016\/j.jare.2024.03.027.","journal-title":"J Adv Res"},{"issue":"23","key":"3595_CR84","doi-asserted-by":"publisher","first-page":"5091","DOI":"10.1113\/jp271016","volume":"593","author":"JC Kim","year":"2015","unstructured":"Kim JC, Woo SH. Shear stress induces a longitudinal Ca(2+) wave via autocrine activation of P2Y1 purinergic signalling in rat atrial myocytes. J Physiol. 2015;593(23):5091\u2013109. https:\/\/doi.org\/10.1113\/jp271016.","journal-title":"J Physiol"},{"issue":"5","key":"3595_CR85","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.bbamem.2009.03.006","volume":"1788","author":"L Welter-Stahl","year":"2009","unstructured":"Welter-Stahl L, da Silva CM, Schachter J, Persechini PM, Souza HS, Ojcius DM, et al. Expression of purinergic receptors and modulation of P2X7 function by the inflammatory cytokine IFN\u03b3 in human epithelial cells. Biochim et Biophys Acta (BBA) - Biomembr. 2009;1788(5):1176\u201387. https:\/\/doi.org\/10.1016\/j.bbamem.2009.03.006.","journal-title":"Biochim et Biophys Acta (BBA) - Biomembr"},{"key":"3595_CR86","doi-asserted-by":"publisher","unstructured":"Strassheim D, Verin A, Batori R, Nijmeh H, Burns N, Kovacs-Kasa A, et al. P2Y Purinergic Receptors, Endothelial Dysfunction, and Cardiovascular Diseases. Int J Mol Sci. 2020;21(18). https:\/\/doi.org\/10.3390\/ijms21186855.","DOI":"10.3390\/ijms21186855"},{"issue":"8","key":"3595_CR87","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1161\/atvbaha.116.307739","volume":"36","author":"G Kauffenstein","year":"2016","unstructured":"Kauffenstein G, Tamareille S, Prunier F, Roy C, Ayer A, Toutain B, et al. Central Role of P2Y6 UDP Receptor in Arteriolar Myogenic Tone. Arterioscler Thromb Vasc Biol. 2016;36(8):1598\u2013606. https:\/\/doi.org\/10.1161\/atvbaha.116.307739.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3595_CR88","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3389\/fendo.2020.00329","volume":"11","author":"M Martin-Aragon Baudel","year":"2020","unstructured":"Martin-Aragon Baudel M, Espinosa-Tanguma R, Nieves-Cintron M, Navedo MF. Purinergic Signaling During Hyperglycemia in Vascular Smooth Muscle Cells. Front Endocrinol (Lausanne). 2020;11:329. https:\/\/doi.org\/10.3389\/fendo.2020.00329.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"3595_CR89","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1172\/jci17864","volume":"112","author":"P Andre","year":"2003","unstructured":"Andre P, Delaney SM, LaRocca T, Vincent D, DeGuzman F, Jurek M, et al. P2Y12 regulates platelet adhesion\/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest. 2003;112(3):398\u2013406. https:\/\/doi.org\/10.1172\/jci17864.","journal-title":"J Clin Invest"},{"issue":"3","key":"3595_CR90","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1172\/jci20986","volume":"113","author":"RT Dorsam","year":"2004","unstructured":"Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest. 2004;113(3):340\u20135. https:\/\/doi.org\/10.1172\/jci20986.","journal-title":"J Clin Invest"},{"issue":"10","key":"3595_CR91","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1111\/j.1538-7836.2005.01588.x","volume":"3","author":"C Soulet","year":"2005","unstructured":"Soulet C, Hechler B, Gratacap MP, Plantavid M, Offermanns S, Gachet C, et al. A differential role of the platelet ADP receptors P2Y1 and P2Y12 in Rac activation. J Thromb Haemost. 2005;3(10):2296\u2013306. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01588.x.","journal-title":"J Thromb Haemost"},{"issue":"18","key":"3595_CR92","doi-asserted-by":"publisher","first-page":"9984","DOI":"10.1073\/pnas.180194597","volume":"97","author":"J Yang","year":"2000","unstructured":"Yang J, Wu J, Kowalska MA, Dalvi A, Prevost N, O\u2019Brien PJ, et al. Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs. Proc Natl Acad Sci U S A. 2000;97(18):9984\u20139. https:\/\/doi.org\/10.1073\/pnas.180194597.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"3595_CR93","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1161\/01.Res.0000251742.71301.16","volume":"99","author":"S Offermanns","year":"2006","unstructured":"Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res. 2006;99(12):1293\u2013304. https:\/\/doi.org\/10.1161\/01.Res.0000251742.71301.16.","journal-title":"Circ Res"},{"issue":"2","key":"3595_CR94","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11302-005-6209-x","volume":"1","author":"C L\u00e9on","year":"2005","unstructured":"L\u00e9on C, Freund M, Latchoumanin O, Farret A, Petit P, Cazenave J-P, et al. The P2Y1 receptor is involved in the maintenance of glucose homeostasis and in insulin secretion in mice. Purinergic Signalling. 2005;1(2):145\u201351. https:\/\/doi.org\/10.1007\/s11302-005-6209-x.","journal-title":"Purinergic Signalling"},{"key":"3595_CR95","doi-asserted-by":"publisher","first-page":"101867","DOI":"10.1016\/j.molmet.2023.101867","volume":"79","author":"A Dance","year":"2024","unstructured":"Dance A, Fernandes J, Toussaint B, Vaillant E, Boutry R, Baron M, et al. Exploring the role of purinergic receptor P2RY1 in type 2 diabetes risk and pathophysiology: Insights from human functional genomics. Mol Metab. 2024;79:101867. https:\/\/doi.org\/10.1016\/j.molmet.2023.101867.","journal-title":"Mol Metab"},{"issue":"15","key":"3595_CR96","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.1182\/bloodadvances.2022007007","volume":"6","author":"X Zhao","year":"2022","unstructured":"Zhao X, Cooper M, Michael JV, Yarman Y, Baltz A, Chuprun JK, et al. GRK2 regulates ADP signaling in platelets via P2Y1 and P2Y12. Blood Adv. 2022;6(15):4524\u201336. https:\/\/doi.org\/10.1182\/bloodadvances.2022007007.","journal-title":"Blood Adv"},{"issue":"16","key":"3595_CR97","doi-asserted-by":"publisher","first-page":"11050","DOI":"10.1074\/jbc.M709266200","volume":"283","author":"RC Choi","year":"2008","unstructured":"Choi RC, Simon J, Tsim KW, Barnard EA. Constitutive and agonist-induced dimerizations of the P2Y1 receptor: relationship to internalization and scaffolding. J Biol Chem. 2008;283(16):11050\u201363. https:\/\/doi.org\/10.1074\/jbc.M709266200.","journal-title":"J Biol Chem"},{"key":"3595_CR98","doi-asserted-by":"publisher","unstructured":"Chaudhary PK, Kim S, Jee Y, Lee SH, Park KM, Kim S. Role of GRK6 in the Regulation of Platelet Activation through Selective G Protein-Coupled Receptor (GPCR) Desensitization. Int J Mol Sci. 2020;21(11). https:\/\/doi.org\/10.3390\/ijms21113932.","DOI":"10.3390\/ijms21113932"},{"issue":"44","key":"3595_CR99","doi-asserted-by":"publisher","first-page":"45354","DOI":"10.1074\/jbc.M408962200","volume":"279","author":"A Moers","year":"2004","unstructured":"Moers A, Wettschureck N, Gr\u00fcner S, Nieswandt B, Offermanns S. Unresponsiveness of platelets lacking both Galpha(q) and Galpha(13). Implications for collagen-induced platelet activation. J Biol Chem. 2004;279(44):45354\u20139. https:\/\/doi.org\/10.1074\/jbc.M408962200.","journal-title":"J Biol Chem"},{"key":"3595_CR100","doi-asserted-by":"publisher","first-page":"29","DOI":"10.20517\/2574-1209.2025.114","volume":"9","author":"C-Y Zou","year":"2025","unstructured":"Zou C-Y, Deng Y-T, Lin X-R, Xie H-Q. Multi-functional platelets: translating biological functions into therapeutic applications. Vessel Plus. 2025;9:29. https:\/\/doi.org\/10.20517\/2574-1209.2025.114.","journal-title":"Vessel Plus"},{"issue":"4","key":"3595_CR101","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/bph.16191","volume":"181","author":"D Pan","year":"2024","unstructured":"Pan D, Ladds G, Rahman KM, Pitchford SC. Exploring bias in platelet P2Y(1) signalling: Host defence versus haemostasis. Br J Pharmacol. 2024;181(4):580\u201392. https:\/\/doi.org\/10.1111\/bph.16191.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"3595_CR102","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1161\/01.cir.103.5.718","volume":"103","author":"C L\u00e9on","year":"2001","unstructured":"L\u00e9on C, Freund M, Ravanat C, Baurand A, Cazenave JP, Gachet C. Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. Circulation. 2001;103(5):718\u201323. https:\/\/doi.org\/10.1161\/01.cir.103.5.718.","journal-title":"Circulation"},{"issue":"2","key":"3595_CR103","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11239-012-0745-3","volume":"34","author":"JE Bird","year":"2012","unstructured":"Bird JE, Wang X, Smith PL, Barbera F, Huang C, Schumacher WA. A platelet target for venous thrombosis? P2Y1 deletion or antagonism protects mice from vena cava thrombosis. J Thromb Thrombolysis. 2012;34(2):199\u2013207. https:\/\/doi.org\/10.1007\/s11239-012-0745-3.","journal-title":"J Thromb Thrombolysis"},{"issue":"10","key":"3595_CR104","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/13522","volume":"5","author":"JE Fabre","year":"1999","unstructured":"Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM, et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med. 1999;5(10):1199\u2013202. https:\/\/doi.org\/10.1038\/13522.","journal-title":"Nat Med"},{"issue":"2","key":"3595_CR105","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1055\/s-2005-869518","volume":"31","author":"MA Packham","year":"2005","unstructured":"Packham MA, Mustard JF. Platelet aggregation and adenosine diphosphate\/adenosine triphosphate receptors: a historical perspective. Semin Thromb Hemost. 2005;31(2):129\u201338. https:\/\/doi.org\/10.1055\/s-2005-869518.","journal-title":"Semin Thromb Hemost"},{"issue":"Suppl 4","key":"3595_CR106","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/hae.12427","volume":"20","author":"MC Berndt","year":"2014","unstructured":"Berndt MC, Metharom P, Andrews RK. Primary haemostasis: newer insights. Haemophilia. 2014;20(Suppl 4):15\u201322. https:\/\/doi.org\/10.1111\/hae.12427.","journal-title":"Haemophilia"},{"issue":"3","key":"3595_CR107","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1124\/pr.117.014530","volume":"70","author":"J Yeung","year":"2018","unstructured":"Yeung J, Li W, Holinstat M. Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases. Pharmacol Rev. 2018;70(3):526\u201348. https:\/\/doi.org\/10.1124\/pr.117.014530.","journal-title":"Pharmacol Rev"},{"issue":"17","key":"3595_CR108","doi-asserted-by":"publisher","first-page":"6065","DOI":"10.3390\/ijms21176065","volume":"21","author":"A G\u0105secka","year":"2020","unstructured":"G\u0105secka A, Rogula S, Eyileten C, Postu\u0142a M, Jaguszewski MJ, Kochman J, et al. Role of P2Y Receptors in Platelet Extracellular Vesicle Release. Int J Mol Sci. 2020;21(17):6065.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3595_CR109","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1161\/atvbaha.114.304509","volume":"35","author":"ZA Karim","year":"2015","unstructured":"Karim ZA, Vemana HP, Alshbool FZ, Lin OA, Alshehri AM, Javaherizadeh P, et al. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor. Arterioscler Thromb Vasc Biol. 2015;35(3):637\u201344. https:\/\/doi.org\/10.1161\/atvbaha.114.304509.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"3595_CR110","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s11239-015-1302-7","volume":"41","author":"PC Wong","year":"2016","unstructured":"Wong PC, Watson C, Crain EJ. The P2Y1 receptor antagonist MRS2500 prevents carotid artery thrombosis in cynomolgus monkeys. J Thromb Thrombolysis. 2016;41(3):514\u201321. https:\/\/doi.org\/10.1007\/s11239-015-1302-7.","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"3595_CR111","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.3390\/ijms26031206","volume":"26","author":"RA Sophocleous","year":"2025","unstructured":"Sophocleous RA, Curtis SJ, Curtis BL, Ooi L, Sluyter R. P2Y1 and P2Y12 Receptors Mediate Aggregation of Dog and Cat Platelets: A Comparison to Human Platelets. Int J Mol Sci. 2025;26(3):1206.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3595_CR112","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1160\/th12-11-0853","volume":"110","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Liu X, Liu L, Zaske AM, Zhou Z, Fu Y, et al. Contact- and agonist-regulated microvesiculation of human platelets. Thromb Haemost. 2013;110(2):331\u20139. https:\/\/doi.org\/10.1160\/th12-11-0853.","journal-title":"Thromb Haemost"},{"issue":"1","key":"3595_CR113","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12931-026-03611-8","volume":"27","author":"D Pan","year":"2026","unstructured":"Pan D, Lino-Alvarado A, Amison RT, Oralman T, Evans R, Baker O, et al. Platelet-specific P2Y1 receptor deficient mice have suppressed pulmonary leukocyte recruitment in response to lipopolysaccharide. Respir Res. 2026;27(1):165. https:\/\/doi.org\/10.1186\/s12931-026-03611-8.","journal-title":"Respir Res"},{"issue":"2","key":"3595_CR114","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jaci.2014.09.032","volume":"135","author":"RT Amison","year":"2015","unstructured":"Amison RT, Momi S, Morris A, Manni G, Keir S, Gresele P, et al. RhoA signaling through platelet P2Y\u2081 receptor controls leukocyte recruitment in allergic mice. J Allergy Clin Immunol. 2015;135(2):528\u201338. https:\/\/doi.org\/10.1016\/j.jaci.2014.09.032.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"3595_CR115","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1474-8673.1996.tb00040.x","volume":"16","author":"TE Webb","year":"1996","unstructured":"Webb TE, Boluyt MO, Barnard EA. Molecular biology of P2Y purinoceptors: expression in rat heart. J Auton Pharmacol. 1996;16(6):303\u20137. https:\/\/doi.org\/10.1111\/j.1474-8673.1996.tb00040.x.","journal-title":"J Auton Pharmacol"},{"issue":"10","key":"3595_CR116","doi-asserted-by":"publisher","first-page":"e1001674","DOI":"10.1371\/journal.pbio.1001674","volume":"11","author":"A Sledzi\u0144ska","year":"2013","unstructured":"Sledzi\u0144ska A, Hemmers S, Mair F, Gorka O, Ruland J, Fairbairn L, et al. TGF-\u03b2 signalling is required for CD4\u207a T cell homeostasis but dispensable for regulatory T cell function. PLoS Biol. 2013;11(10):e1001674. https:\/\/doi.org\/10.1371\/journal.pbio.1001674.","journal-title":"PLoS Biol"},{"key":"3595_CR117","doi-asserted-by":"publisher","first-page":"627773","DOI":"10.3389\/fphar.2021.627773","volume":"12","author":"G Tian","year":"2021","unstructured":"Tian G, Zhou J, Quan Y, Kong Q, Wu W, Liu X. P2Y1 Receptor Agonist Attenuates Cardiac Fibroblasts Activation Triggered by TGF-\u03b21. Front Pharmacol. 2021;12:627773. https:\/\/doi.org\/10.3389\/fphar.2021.627773.","journal-title":"Front Pharmacol"},{"issue":"6","key":"3595_CR118","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/fjc.0000000000000822","volume":"75","author":"T Deng","year":"2020","unstructured":"Deng T, Wei Z, Gael A, Deng X, Liu Y, Lai J, et al. Higenamine Improves Cardiac and Renal Fibrosis in Rats With Cardiorenal Syndrome via ASK1 Signaling Pathway. J Cardiovasc Pharmacol. 2020;75(6):535\u201344. https:\/\/doi.org\/10.1097\/fjc.0000000000000822.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"3595_CR119","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00018-016-2365-0","volume":"74","author":"R Sathanoori","year":"2017","unstructured":"Sathanoori R, Bryl-Gorecka P, M\u00fcller CE, Erb L, Weisman GA, Olde B, et al. P2Y(2) receptor modulates shear stress-induced cell alignment and actin stress fibers in human umbilical vein endothelial cells. Cell Mol Life Sci. 2017;74(4):731\u201346. https:\/\/doi.org\/10.1007\/s00018-016-2365-0.","journal-title":"Cell Mol Life Sci"},{"key":"3595_CR120","doi-asserted-by":"publisher","unstructured":"Wei L, Mousawi F, Li D, Roger S, Li J, Yang X, et al. Adenosine Triphosphate Release and P2 Receptor Signaling in Piezo1 Channel-Dependent Mechanoregulation. Front Pharmacol. 2019;10 :01304. https:\/\/doi.org\/10.3389\/fphar.2019.01304","DOI":"10.3389\/fphar.2019.01304"},{"issue":"6","key":"3595_CR121","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1161\/circulationaha.108.764571","volume":"119","author":"CG da Silva","year":"2009","unstructured":"da Silva CG, Specht A, Wegiel B, Ferran C, Kaczmarek E. Mechanism of purinergic activation of endothelial nitric oxide synthase in endothelial cells. Circulation. 2009;119(6):871\u20139. https:\/\/doi.org\/10.1161\/circulationaha.108.764571.","journal-title":"Circulation"},{"issue":"3","key":"3595_CR122","doi-asserted-by":"publisher","first-page":"e13268","DOI":"10.1111\/apha.13268","volume":"226","author":"C Cabou","year":"2019","unstructured":"Cabou C, Honorato P, Brice\u00f1o L, Ghezali L, Duparc T, Le\u00f3n M, et al. Pharmacological inhibition of the F(1)-ATPase\/P2Y(1) pathway suppresses the effect of apolipoprotein A1 on endothelial nitric oxide synthesis and vasorelaxation. Acta Physiol (Oxf). 2019;226(3):e13268. . https:\/\/doi.org\/10.1111\/apha.13268","journal-title":"Acta Physiol (Oxf)"},{"issue":"1","key":"3595_CR123","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.atherosclerosis.2014.11.017","volume":"238","author":"LO Martinez","year":"2015","unstructured":"Martinez LO, Najib S, Perret B, Cabou C, Lichtenstein L. Ecto-F1-ATPase\/P2Y pathways in metabolic and vascular functions of high density lipoproteins. Atherosclerosis. 2015;238(1):89\u2013100. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.11.017.","journal-title":"Atherosclerosis"},{"issue":"1","key":"3595_CR124","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1161\/atvbaha.111.238063","volume":"32","author":"C Cavelier","year":"2012","unstructured":"Cavelier C, Ohnsorg PM, Rohrer L, von Eckardstein A. The \u03b2-chain of cell surface F(0)F(1) ATPase modulates apoA-I and HDL transcytosis through aortic endothelial cells. Arterioscler Thromb Vasc Biol. 2012;32(1):131\u20139. https:\/\/doi.org\/10.1161\/atvbaha.111.238063.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3595_CR125","doi-asserted-by":"publisher","unstructured":"Cabou C, Martinez LO. The Interplay of Endothelial P2Y Receptors in Cardiovascular Health: From Vascular Physiology to Pathology. Int J Mol Sci. 2022;23(11):21115833. https:\/\/doi.org\/10.3390\/ijms23115883","DOI":"10.3390\/ijms23115883"},{"issue":"21","key":"3595_CR126","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/circulationaha.110.002139","volume":"123","author":"M Zerr","year":"2011","unstructured":"Zerr M, Hechler B, Freund M, Magnenat S, Lanois I, Cazenave JP, et al. Major contribution of the P2Y\u2081receptor in purinergic regulation of TNF\u03b1-induced vascular inflammation. Circulation. 2011;123(21):2404\u201313. . https:\/\/doi.org\/10.1161\/circulationaha.110.002139","journal-title":"Circulation"},{"issue":"7","key":"3595_CR127","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1161\/circulationaha.108.788927","volume":"118","author":"B Hechler","year":"2008","unstructured":"Hechler B, Freund M, Ravanat C, Magnenat S, Cazenave JP, Gachet C. Reduced atherosclerotic lesions in P2Y1\/apolipoprotein E double-knockout mice: the contribution of non-hematopoietic-derived P2Y1 receptors. Circulation. 2008;118(7):754\u201363. https:\/\/doi.org\/10.1161\/circulationaha.108.788927.","journal-title":"Circulation"},{"issue":"2","key":"3595_CR128","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1160\/th13-12-1026","volume":"112","author":"A Assinger","year":"2014","unstructured":"Assinger A, Wang Y, Butler LM, Hansson GK, Yan ZQ, S\u00f6derberg-Naucl\u00e9r C, et al. Apolipoprotein B100 danger-associated signal 1 (ApoBDS-1) triggers platelet activation and boosts platelet-leukocyte proinflammatory responses. Thromb Haemost. 2014;112(2):332\u201341. https:\/\/doi.org\/10.1160\/th13-12-1026.","journal-title":"Thromb Haemost"},{"issue":"1","key":"3595_CR129","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1182\/blood.v99.1.193","volume":"99","author":"J Jin","year":"2002","unstructured":"Jin J, Quinton TM, Zhang J, Rittenhouse SE, Kunapuli SP. Adenosine diphosphate (ADP)-induced thromboxane A(2) generation in human platelets requires coordinated signaling through integrin alpha(IIb)beta(3) and ADP receptors. Blood. 2002;99(1):193\u20138. https:\/\/doi.org\/10.1182\/blood.v99.1.193.","journal-title":"Blood"},{"issue":"6116","key":"3595_CR130","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1126\/science.1230719","volume":"339","author":"FK Swirski","year":"2013","unstructured":"Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science. 2013;339(6116):161\u20136. https:\/\/doi.org\/10.1126\/science.1230719.","journal-title":"Science"},{"issue":"2","key":"3595_CR131","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1253\/circj.cj-09-0706","volume":"74","author":"P Libby","year":"2010","unstructured":"Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: transition from theory to practice. Circ J. 2010;74(2):213\u201320. https:\/\/doi.org\/10.1253\/circj.cj-09-0706.","journal-title":"Circ J"},{"issue":"4","key":"3595_CR132","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0031-6997(25)06812-7","volume":"46","author":"HH Dalziel","year":"1994","unstructured":"Dalziel HH, Westfall DP. Receptors for adenine nucleotides and nucleosides: subclassification, distribution, and molecular characterization. Pharmacol Rev. 1994;46(4):449\u201366.","journal-title":"Pharmacol Rev"},{"issue":"10","key":"3595_CR133","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/01.ATV.0000142376.30582.ed","volume":"24","author":"AK Wihlborg","year":"2004","unstructured":"Wihlborg AK, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, Gudbjartsson T, et al. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol. 2004;24(10):1810\u20135. https:\/\/doi.org\/10.1161\/01.ATV.0000142376.30582.ed.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3595_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yjmcc.2020.02.004","volume":"140","author":"R Zhou","year":"2020","unstructured":"Zhou R, Dang X, Sprague RS, Mustafa SJ, Zhou Z. Alteration of purinergic signaling in diabetes: Focus on vascular function. J Mol Cell Cardiol. 2020;140:1\u20139. https:\/\/doi.org\/10.1016\/j.yjmcc.2020.02.004.","journal-title":"J Mol Cell Cardiol"},{"key":"3595_CR135","doi-asserted-by":"publisher","first-page":"117613","DOI":"10.1016\/j.atherosclerosis.2024.117613","volume":"395","author":"X Chen","year":"2024","unstructured":"Chen X, Obukhov AG, Weisman GA, Seye CI. Basal ATP release signals through the P2Y(2) receptor to maintain the differentiated phenotype of vascular smooth muscle cells. Atherosclerosis. 2024;395:117613. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2024.117613.","journal-title":"Atherosclerosis"},{"issue":"3","key":"3595_CR136","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1006\/bbrc.1998.9083","volume":"248","author":"D Erlinge","year":"1998","unstructured":"Erlinge D, Hou M, Webb TE, Barnard EA, M\u00f6ller S. Phenotype changes of the vascular smooth muscle cell regulate P2 receptor expression as measured by quantitative RT-PCR. Biochem Biophys Res Commun. 1998;248(3):864\u201370. https:\/\/doi.org\/10.1006\/bbrc.1998.9083.","journal-title":"Biochem Biophys Res Commun"},{"issue":"411","key":"3595_CR137","doi-asserted-by":"publisher","first-page":"ra7","DOI":"10.1126\/scisignal.aac9187","volume":"9","author":"A Nishimura","year":"2016","unstructured":"Nishimura A, Sunggip C, Tozaki-Saitoh H, Shimauchi T, Numaga-Tomita T, Hirano K, et al. Purinergic P2Y6 receptors heterodimerize with angiotensin AT1 receptors to promote angiotensin II-induced hypertension. Sci Signal. 2016;9(411):ra7. https:\/\/doi.org\/10.1126\/scisignal.aac9187.","journal-title":"Sci Signal"},{"issue":"2","key":"3595_CR138","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jphs.2024.01.003","volume":"154","author":"K Nishiyama","year":"2024","unstructured":"Nishiyama K. The role of P2Y(6) receptor in the pathogenesis of cardiovascular and inflammatory diseases. J Pharmacol Sci. 2024;154(2):108\u201312. https:\/\/doi.org\/10.1016\/j.jphs.2024.01.003.","journal-title":"J Pharmacol Sci"},{"issue":"2","key":"3595_CR139","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1161\/hypertensionaha.113.01487","volume":"62","author":"IC Wenker","year":"2013","unstructured":"Wenker IC, Sobrinho CR, Takakura AC, Mulkey DK, Moreira TS. P2Y1 receptors expressed by C1 neurons determine peripheral chemoreceptor modulation of breathing, sympathetic activity, and blood pressure. Hypertension. 2013;62(2):263\u201373. https:\/\/doi.org\/10.1161\/hypertensionaha.113.01487.","journal-title":"Hypertension"},{"issue":"27","key":"3595_CR140","doi-asserted-by":"publisher","first-page":"7230","DOI":"10.1523\/jneurosci.1696-06.2006","volume":"26","author":"DK Mulkey","year":"2006","unstructured":"Mulkey DK, Mistry AM, Guyenet PG, Bayliss DA. Purinergic P2 receptors modulate excitability but do not mediate pH sensitivity of RTN respiratory chemoreceptors. J Neurosci. 2006;26(27):7230\u20133. https:\/\/doi.org\/10.1523\/jneurosci.1696-06.2006.","journal-title":"J Neurosci"},{"issue":"1","key":"3595_CR141","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1113\/ep088169","volume":"105","author":"MR Malheiros-Lima","year":"2020","unstructured":"Malheiros-Lima MR, Antunes VR, Takakura AC, Moreira TS. Hypertension and sympathetic nervous system overactivity rely on the vascular tone of pial vessels of the rostral ventrolateral medulla in spontaneously hypertensive rats. Exp Physiol. 2020;105(1):65\u201374. https:\/\/doi.org\/10.1113\/ep088169.","journal-title":"Exp Physiol"},{"issue":"1","key":"3595_CR142","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12519-022-00621-6","volume":"19","author":"N Shen","year":"2023","unstructured":"Shen N, Wu YF, Chen YW, Fang XY, Zhou M, Wang WY, et al. Clinical characteristics of pediatric cases infected with the SARS-CoV-2 Omicron variant in a tertiary children\u2019s medical center in Shanghai, China. World J Pediatr. 2023;19(1):87\u201395. https:\/\/doi.org\/10.1007\/s12519-022-00621-6.","journal-title":"World J Pediatr"},{"issue":"6","key":"3595_CR143","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","volume":"80","author":"Q Ye","year":"2020","unstructured":"Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm\u2019 in COVID-19. J Infect. 2020;80(6):607\u201313. https:\/\/doi.org\/10.1016\/j.jinf.2020.03.037.","journal-title":"J Infect"},{"key":"3595_CR144","doi-asserted-by":"publisher","first-page":"8632048","DOI":"10.1155\/2020\/8632048","volume":"2020","author":"F Dos Anjos","year":"2020","unstructured":"Dos Anjos F, Sim\u00f5es JLB, Assmann CE, Carvalho FB, Bagatini MD. Potential Therapeutic Role of Purinergic Receptors in Cardiovascular Disease Mediated by SARS-CoV-2. J Immunol Res. 2020;2020:8632048. https:\/\/doi.org\/10.1155\/2020\/8632048.","journal-title":"J Immunol Res"},{"issue":"Pt 3","key":"3595_CR145","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1113\/jphysiol.2003.052258","volume":"552","author":"YK Ju","year":"2003","unstructured":"Ju YK, Huang W, Jiang L, Barden JA, Allen DG. ATP modulates intracellular Ca2\u2009+\u2009 and firing rate through a P2Y1 purinoceptor in cane toad pacemaker cells. J Physiol. 2003;552(Pt 3):777\u201387. . https:\/\/doi.org\/10.1113\/jphysiol.2003.052258","journal-title":"J Physiol"},{"issue":"11","key":"3595_CR146","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1111\/bph.15005","volume":"177","author":"KA Jacobson","year":"2020","unstructured":"Jacobson KA, Delicado EG, Gachet C, Kennedy C, von K\u00fcgelgen I, Li B, et al. Update of P2Y receptor pharmacology: IUPHAR Review 27. Br J Pharmacol. 2020;177(11):2413\u201333. https:\/\/doi.org\/10.1111\/bph.15005.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"3595_CR147","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1527-3466.2003.tb00106.x","volume":"21","author":"A Baurand","year":"2003","unstructured":"Baurand A, Gachet C. The P2Y(1) receptor as a target for new antithrombotic drugs: a review of the P2Y(1) antagonist MRS-2179. Cardiovasc Drug Rev. 2003;21(1):67\u201376. https:\/\/doi.org\/10.1111\/j.1527-3466.2003.tb00106.x.","journal-title":"Cardiovasc Drug Rev"},{"key":"3595_CR148","doi-asserted-by":"publisher","first-page":"239821281881749","DOI":"10.1177\/2398212818817494","volume":"2","author":"G Burnstock","year":"2018","unstructured":"Burnstock G. Purine and purinergic receptors. Brain Neurosci Adv. 2018;2:2398212818817494. https:\/\/doi.org\/10.1177\/2398212818817494.","journal-title":"Brain Neurosci Adv"},{"issue":"22","key":"3595_CR149","doi-asserted-by":"publisher","first-page":"9981","DOI":"10.1021\/acs.jmedchem.5b01972","volume":"59","author":"S Conroy","year":"2016","unstructured":"Conroy S, Kindon N, Kellam B, Stocks MJ. Drug-like Antagonists of P2Y Receptors-From Lead Identification to Drug Development. J Med Chem. 2016;59(22):9981\u201310005. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01972.","journal-title":"J Med Chem"},{"issue":"3","key":"3595_CR150","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/s0014-2999(01)00733-6","volume":"412","author":"A Baurand","year":"2001","unstructured":"Baurand A, Raboisson P, Freund M, L\u00e9on C, Cazenave JP, Bourguignon JJ, et al. Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. Eur J Pharmacol. 2001;412(3):213\u201321. https:\/\/doi.org\/10.1016\/s0014-2999(01)00733-6.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"3595_CR151","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1046\/j.1538-7836.2003.00144.x","volume":"1","author":"N Lenain","year":"2003","unstructured":"Lenain N, Freund M, L\u00e9on C, Cazenave JP, Gachet C. Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist. J Thromb Haemost. 2003;1(6):1144\u20139. https:\/\/doi.org\/10.1046\/j.1538-7836.2003.00144.x.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"3595_CR152","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10557-014-6561-6","volume":"29","author":"R Liu","year":"2015","unstructured":"Liu R, Ma S, Lu Z, Shen H, Sun L, Wei M. The ADP antagonist MRS2179 regulates the phenotype of smooth muscle cells to limit intimal hyperplasia. Cardiovasc Drugs Ther. 2015;29(1):23\u20139. https:\/\/doi.org\/10.1007\/s10557-014-6561-6.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"3595_CR153","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.bcp.2005.11.010","volume":"71","author":"KA Jacobson","year":"2006","unstructured":"Jacobson KA, Costanzi S, Ivanov AA, Tchilibon S, Besada P, Gao ZG, et al. Structure activity and molecular modeling analyses of ribose- and base-modified uridine 5\u2019-triphosphate analogues at the human P2Y2 and P2Y4 receptors. Biochem Pharmacol. 2006;71(4):540\u20139. https:\/\/doi.org\/10.1016\/j.bcp.2005.11.010.","journal-title":"Biochem Pharmacol"},{"issue":"7498","key":"3595_CR154","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature13288","volume":"509","author":"J Zhang","year":"2014","unstructured":"Zhang J, Zhang K, Gao ZG, Paoletta S, Zhang D, Han GW, et al. Agonist-bound structure of the human P2Y12 receptor. Nature. 2014;509(7498):119\u201322. https:\/\/doi.org\/10.1038\/nature13288.","journal-title":"Nature"},{"issue":"5","key":"3595_CR155","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/procel\/pwac025","volume":"14","author":"B Li","year":"2023","unstructured":"Li B, Han S, Wang M, Yu Y, Ma L, Chu X, et al. Structural insights into signal transduction of the purinergic receptors P2Y1R and P2Y12R. Protein Cell. 2023;14(5):382\u20136. https:\/\/doi.org\/10.1093\/procel\/pwac025.","journal-title":"Protein Cell"},{"key":"3595_CR156","doi-asserted-by":"publisher","unstructured":"Mahdi A, Jiao T, Tratsiakovich Y, Yang J, \u00d6stenson CG, Pernow J, et al. Altered Purinergic Receptor Sensitivity in Type 2 Diabetes-Associated Endothelial Dysfunction and Up\u2084A-Mediated Vascular Contraction. Int J Mol Sci. 2018;19(12) :19123942. https:\/\/doi.org\/10.3390\/ijms19123942","DOI":"10.3390\/ijms19123942"},{"key":"3595_CR157","doi-asserted-by":"publisher","unstructured":"Marcheva B, Weidemann BJ, Taguchi A, Perelis M, Ramsey KM, Newman MV, et al. P2Y1 purinergic receptor identified as a diabetes target in a small-molecule screen to reverse circadian \u03b2-cell failure. Elife. 2022;11:75132. https:\/\/doi.org\/10.7554\/eLife.75132","DOI":"10.7554\/eLife.75132"},{"issue":"6","key":"3595_CR158","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/wmts.97","volume":"2","author":"C Gachet","year":"2013","unstructured":"Gachet C, Hechler B. The P2Y receptors and thrombosis. Wiley Interdisciplinary Reviews: Membrane Transp Signal. 2013;2(6):241\u201353. https:\/\/doi.org\/10.1002\/wmts.97.","journal-title":"Wiley Interdisciplinary Reviews: Membrane Transp Signal"},{"issue":"7","key":"3595_CR159","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1182\/blood-2010-08-263111","volume":"117","author":"M Cattaneo","year":"2011","unstructured":"Cattaneo M. The platelet P2Y\u2081\u2082 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood. 2011;117(7):2102\u201312. https:\/\/doi.org\/10.1182\/blood-2010-08-263111.","journal-title":"Blood"},{"issue":"4","key":"3595_CR160","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1161\/atvbaha.118.310224","volume":"38","author":"SP Grover","year":"2018","unstructured":"Grover SP, Bergmeier W, Mackman N. Platelet Signaling Pathways and New Inhibitors. Arterioscler Thromb Vasc Biol. 2018;38(4):e28\u201335. https:\/\/doi.org\/10.1161\/atvbaha.118.310224.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"3595_CR161","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/j.1365-2125.2011.03999.x","volume":"72","author":"YD Wijeyeratne","year":"2011","unstructured":"Wijeyeratne YD, Heptinstall S. Anti-platelet therapy: ADP receptor antagonists. Br J Clin Pharmacol. 2011;72(4):647\u201357. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.03999.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3595_CR162","doi-asserted-by":"publisher","first-page":"14529","DOI":"10.1038\/s41598-018-32797-1","volume":"8","author":"E Smolensky Koganov","year":"2018","unstructured":"Smolensky Koganov E, Michelson AD, Yanachkov IB, Yanachkova MI, Wright GE, Przyklenk K, et al. GLS-409, an Antagonist of Both P2Y(1) and P2Y(12), Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Sci Rep. 2018;8(1):14529. https:\/\/doi.org\/10.1038\/s41598-018-32797-1.","journal-title":"Sci Rep"},{"issue":"3","key":"3595_CR163","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1161\/atvbaha.115.306885","volume":"36","author":"T Gremmel","year":"2016","unstructured":"Gremmel T, Yanachkov IB, Yanachkova MI, Wright GE, Wider J, Undyala VV, et al. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. Arterioscler Thromb Vasc Biol. 2016;36(3):501\u20139. https:\/\/doi.org\/10.1161\/atvbaha.115.306885.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"16","key":"3595_CR164","doi-asserted-by":"publisher","first-page":"17990","DOI":"10.1021\/acs.jmedchem.5c01780","volume":"68","author":"B Zhang","year":"2025","unstructured":"Zhang B, Li J, Wang R, Li Q, Mao Q, Fu X, et al. Discovery of 1-Difluoromethyl-3-(3-cyanophenyl)-6-[4-(trifluoromethoxy)phenyl]imidazo[1,5-a]pyrazin-8-(7H)-one as a Potent P2Y(1) Antagonist for the Treatment of Ischemic Stroke and Myocardial Infarction. J Med Chem. 2025;68(16):17990\u20138015. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01780.","journal-title":"J Med Chem"},{"key":"3595_CR165","doi-asserted-by":"publisher","unstructured":"Al Meanazel O, Alshbool FZ, Khasawneh FT. Design and Pharmacological Characterization of a Novel Antithrombotic P2Y(1) Receptor-Based Vaccine. Int J Mol Sci. 2025;26(9). https:\/\/doi.org\/10.3390\/ijms26094383.","DOI":"10.3390\/ijms26094383"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03595-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00044-026-03595-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03595-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:41:49Z","timestamp":1792039309000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00044-026-03595-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":165,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3595"],"URL":"https:\/\/doi.org\/10.1007\/s00044-026-03595-6","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"5 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}